Successful treatment of eruptive keratoacanthomas with actitretin for patients on checkpoint inhibitor immunotherapy

R J Schwartz; G Ho; A Smith; H Collgros; A Regio Pereira; B Gouveia; G V Long; A M Menzies; A J Potter; E Paver; P Star; R A Scolyer; L K Martin

doi:10.1111/jdv.17940

Successful treatment of eruptive keratoacanthomas with actitretin for patients on checkpoint inhibitor immunotherapy

J Eur Acad Dermatol Venereol. 2022 Jun;36(6):e445-e448. doi: 10.1111/jdv.17940. Epub 2022 Jan 28.

Authors

R J Schwartz^{1

2}, G Ho^{1

3}, A Smith^{1

3}, H Collgros^{3

4}, A Regio Pereira^{3

4

5}, B Gouveia¹, G V Long^{1

3

6

7}, A M Menzies^{1

3

6}, A J Potter^{1

3

8

9}, E Paver^{1

3

9}, P Star¹, R A Scolyer^{1

3

7

9}, L K Martin^{1

3

8}

Affiliations

¹ Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
² Department of Dermatology, Faculty of Medicine, University of Chile, Santiago, Chile.
³ Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
⁴ Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
⁵ Federal University of Sao Paulo, Sao Paulo, Brazil.
⁶ Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.
⁷ Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
⁸ Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia.
⁹ Tissue and Pathology Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia.

PMID: 35043483
DOI: 10.1111/jdv.17940

No abstract available

Publication types

Letter

MeSH terms

Humans
Immunologic Factors
Immunotherapy
Keratoacanthoma* / drug therapy

Substances

Immunologic Factors